Viewing nowTerabia Tablet 25 mg (Sitagliptin Hydrochloride Monohydrate)
Sitagliptin Hydrochloride Hydrate 28.35mg
Tablet · Prescription medication
Teragen Etex Co., Ltd.

MFDS item code 202101860 · Approved 2021.02.24 · Insurance code 698504750
Improvement of glycemic control in type 2 diabetes mellitus
This medication is used to help control blood sugar levels in patients with type 2 diabetes. It can be administered alone or in combination with other diabetes medications alongside dietary and exercise therapy. It may be used in conjunction with Metformin when blood sugar control is difficult with monotherapy and no prior experience with diabetes drug therapy. Additionally, it helps manage blood sugar in cases where there is insufficient effect from monotherapy with sulfonylureas, Metformin, thiazolidinediones, or insulin. For those struggling with blood sugar control through a combination therapy approach, better blood sugar control may be expected by administering this medication with other agents. Therefore, this drug is effective in improving blood glucose management in patients with type 2 diabetes.
Administer 100 mg once daily as monotherapy or in combination therapy; the maximum daily dose is 100 mg. This medicine may be taken with or without food. When coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). Patients with renal impairment Because dosage adjustment is required according to renal function, assessment of renal function is recommended before starting this medicine and periodically during treatment. 1. No dosage adjustment is required in patients with mild renal impairment (glomerular filtration rate [eGFR] ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dosage adjustment is required in patients with moderate renal impairment (glomerular filtration rate [eGFR] ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. Administer 50 mg once daily in patients with moderate renal impairment (glomerular filtration rate [eGFR] ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2). 4. Administer 25 mg once daily in patients with severe renal impairment (glomerular filtration rate [eGFR] ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2). This medicine may be administered regardless of the timing of dialysis.
This medication can cause severe allergic reactions; if symptoms such as skin rash or difficulty breathing occur after administration, discontinue use immediately and consult a physician. During treatment, serious pancreatic inflammation known as pancreatitis may occur, so report any symptoms such as abdominal pain or vomiting to healthcare personnel immediately. This medication should not be used in patients with type 1 diabetes or diabetic ketoacidosis, nor in those allergic to this drug or any of its ingredients. Patients with impaired kidney function need dosage adjustments, so regular kidney function tests should be performed and taken as directed by a physician. In clinical trials, this drug showed a side effect profile similar to other blood glucose-lowering agents, but caution is advised as hypoglycemia may occur. When taken with insulin or sulfonylureas, the risk of hypoglycemia may increase, thus dosage adjustments may be necessary. Long-term use may result in headaches, upper respiratory infections, pharyngitis, peripheral edema, etc., and if symptoms are severe, consultation with a physician is recommended. This medication is not recommended for pregnant women and should be avoided by breastfeeding women. Its safety and efficacy in children and adolescents under 18 years have not been established, so use is advised against. When administering to the elderly, dosage should be carefully considered due to the potential for decreased kidney function. In case of overdose, standard symptomatic treatment is performed, and blood dialysis may be necessary to remove the drug if required. If symptoms such as joint pain or skin blisters occur during treatment, notify a physician immediately, and discontinue the medication in severe cases. There are few drug interactions with this medication, but blood levels should be monitored when taking drugs such as digoxin. It is important to consult healthcare personnel immediately if unusual symptoms occur during treatment to receive appropriate care.
Anaphylaxis, angioedema, Stevens-Johnson syndrome, acute pancreatitis, hypoglycemia, nasopharyngitis, upper respiratory infection, headache, diarrhea, abdominal pain, nausea, peripheral edema, constipation, vomiting, severe and disability-associated arthralgia, bullous pemphigoid, myalgia, limb pain, back pain, interstitial lung disease, pruritus, thrombocytopenia, rhabdomyolysis, elevated liver enzymes, acute renal failure, pneumonia, diabetes complications, metabolic acidosis, falls, cardiac arrest, dyspepsia, dizziness, increased serum triglycerides, gastritis, weight loss, hypertension, hypernatremia, erectile dysfunction
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in an airtight container and kept at room temperature between 1 and 30 degrees Celsius. Storing it this way will maintain the medication's effectiveness and prevent degradation.
Pink, round, biconvex, film-coated tablet
28 Tablets/PTP [(14 Tablets/PTP x 2)]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowSitagliptin Hydrochloride Hydrate 28.35mg
Tablet · Prescription medication
Teragen Etex Co., Ltd.

Sitagliptin Hydrochloride Hydrate 113.4mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 113.4mg
Tablet · Prescription medication
Korea United Pharm., Co., Ltd.

Sitagliptin Hydrochloride Hydrate 128.5mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 128.5mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 28.35mg
Tablet · Prescription medication
Daewoong Bio Co., Ltd.

Sitagliptin Hydrochloride Hydrate 56.7mg
Tablet · Prescription medication
Daewoong Bio Co., Ltd.

Sitagliptin Hydrochloride Hydrate 113.4mg
Tablet · Prescription medication
Daewoong Bio Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.